New Stock Issuance - The new stock issued by Hanguo Group is priced at 15.43 RMB per share[1] - The subscription period for the tender offer of ST Kelly is from July 17, 2025, to August 15, 2025[1] Abnormal Fluctuations - Several stocks, including ST Zitian and Guangshengtang, have reported severe abnormal fluctuations[2] - The announcement links for stocks experiencing abnormal fluctuations are provided for investor reference[2] Market Updates - A total of 30 stocks have been listed for trading updates, with various announcements made between July 15 and July 21, 2025[1] - The report includes links to detailed announcements for each stock, ensuring transparency and accessibility for investors[1]

Core Viewpoint - The announcement details the release of share pledges by major shareholder Cai Nanguai, indicating a potential shift in the company's ownership structure and investor sentiment [1]. Group 1: Share Pledge Release - Cai Nanguai, the largest shareholder of Sailong Pharmaceutical Group Co., Ltd., has notified the company about the release of part of his pledged shares, specifically 16,000,000 shares, which accounts for 9.09% of his holdings and 23.70% of the company's total shares [1]. - Cai Nanguai holds a total of 67,512,703 shares, making him the largest shareholder, although he is not the controlling shareholder or actual controller of the company [1]. Group 2: Pledged Shares Overview - As of the announcement date, the total pledged shares by Cai Nanguai and his concerted actors are detailed, with no shares currently frozen or auctioned, and no non-operating fund occupation or illegal guarantees affecting the company's interests [2]. - The company will continue to monitor the changes in shareholding and fulfill its information disclosure obligations in accordance with relevant regulations [2].

| 股东名 称 | 是否为控股 股东或第一 | 本次解除质 押股份数量 | 占其所持 股份比例 | 占公司总 股本比例 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 一致行动人 | （股） | | | | | | | 蔡南桂 | 是 | 16,000,000 | 23.70% | 9.09% | 2024.04 .22 | 2025.07. 16 | 国都证券 股份有限 | | | | | | | | | 公司 | 一、本次解除质押的基本情况 证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-044 赛隆药业集团股份有限公司 关于公司股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）于近日接到公司持股 5%以 上股东蔡南桂先生的通知，获悉蔡南桂先生将其持有的本公司部分股份办理了解 除质押手续，具体事项如下： 三、其他说明 截至本公告日，蔡南桂先生所持公司股份不 ...

Group 1 - The company expects a net profit to be negative for the period from January 1, 2025, to June 30, 2025 [1] - The main reason for the expected loss is the intensified market competition due to the ongoing drug procurement policy, leading to a decrease in drug sales prices and a decline in market demand for certain products [1] - The company's operating revenue and gross margin are expected to decrease compared to the same period last year, contributing to the anticipated operating loss [1] Group 2 - The data related to the performance forecast is based on preliminary calculations by the company's finance department and has not been audited by the accounting firm [1] - The company had reported negative total profit, net profit, and net profit after deducting non-recurring gains and losses for the year 2024, with operating revenue below 300 million [2] - The company's stock was subject to delisting risk warning due to the negative financial results, and if certain conditions are met, the stock may face termination of listing [2]

Group 1 - The company held its fourth supervisory board meeting on July 14, 2025, with all three supervisors present, confirming compliance with relevant laws and regulations [1][2] - The supervisory board approved the company's borrowing from related parties, stating it meets operational needs, enhances financing efficiency, and does not harm the interests of shareholders [2] - The voting results showed unanimous support with 3 votes in favor and no opposition or abstentions [2] Group 2 - The meeting was convened by the chairwoman, Ms. Zhou Bei, and was conducted both in-person and via communication methods [1] - The details of the related party borrowing and transactions were published on the company's official information disclosure platform [1][2]

Group 1 - The independent directors of the company held a special meeting to review related party transactions, specifically regarding a loan from related parties [1] - The review concluded that the loan transaction would meet the company's operational funding needs without harming the interests of the company or its shareholders, particularly minority shareholders [1] - The financing interest rate is deemed reasonable, and the transaction adheres to principles of fairness and impartiality, ensuring no detriment to the company or minority shareholders [1] Group 2 - The independent directors agreed that the related party transaction would not affect the company's independence and that the company would not become reliant on the related parties [1] - The independent directors consented to submit the proposal regarding the loan from related parties to the company's board for further review, with certain directors required to abstain from voting [1]

Transaction Overview - The company plans to borrow up to RMB 160 million from shareholder Cai Nanguo to meet operational and funding needs, with a term of up to 36 months and an annual interest rate of 3.0% [1][2] - The borrowing will not require any form of guarantee, collateral, or pledge [1][3] Related Party Information - Cai Nanguo is a major shareholder (over 5%) and serves as the chairman and CEO of the company, while his spouse, Tang Lin, is also a director [2][4] - The transaction is classified as a related party transaction but does not constitute a major asset restructuring as per regulations [2][4] Pricing Policy and Basis - The transaction adheres to principles of fairness, openness, and reasonableness, with pricing based on the one-year Loan Prime Rate (LPR) published by the People's Bank of China [3][5] - The transaction is deemed fair and reasonable, with no harm to the interests of the company or its shareholders, particularly minority shareholders [3][5] Purpose and Impact - The borrowing is expected to enhance the company's financing efficiency, alleviate financial pressure, and improve risk resistance [3][5] - The transaction will not significantly impact the company's financial status, operational results, or independence [3][5] Independent Board and Supervisory Committee Opinions - The independent board members unanimously agreed that the borrowing meets the company's operational funding needs and does not harm the interests of shareholders [5] - The supervisory committee also supports the transaction, confirming it aligns with the company's development needs and maintains shareholder interests [5]

赛隆药业集团股份有限公司 第四届董事会独立董事 2025 年第二次专门会议审查意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司独立 董事管理办法》、《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》及《公司章程》，作为赛隆药业 集团股份有限公司（以下简称"公司"）独立董事，召开了第四届董事会独立董 事专门会议 2025 年第二次会议，对相关关联交易事项进行了审议，发表意见如 下： 一、《关于公司向关联方借款暨关联交易的议案》的审查意见 经核查，本次借款暨关联交易可以保障公司生产经营的资金需求，不会损害 公司、全体股东特别是中小股东的利益，有利于提高公司融资效率，促进公司的 健康持续发展。本次交易融资利率定价合理，交易遵循公平、公正、公允的原则， 不存在损害上市公司及中小股东利益的情形。该关联交易事项不会对公司独立性 产生影响，公司不会对关联方形成依赖。同意将《关于公司向关联方借款暨关联 交易的议案》提交公司第四届董事会第九次会议审议，关联董事蔡南桂先生、唐 霖女士需回避表决。 独立董事签名： 潘传云 陈小辛 （此页无正文，为赛隆药 ...

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-042 赛隆药业集团股份有限公司 关于公司向关联方借款暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）于2025年7月14日召开第 四届董事会第九次会议、第四届监事会第九次会议，审议通过了《关于公司向 关联方借款暨关联交易的议案》，现将详细内容公告如下： 一、交易概述 为满足公司生产经营及资金周转需求，提高融资效率，公司拟向股东蔡南桂 先生借款，借款总金额不超过人民币 1.6 亿元（可滚动使用），期限不超过 36 个月（自实际放款之日起算），年化利率为 3.0%，参照当前中国人民银行授权全 国银行间同业拆借中心公布的一年期贷款市场报价利率（LPR）计算，借款利息 按实际借款金额和用款天数计算。公司无需提供保证、抵押、质押等任何形式的 担保。 本次交易中，蔡南桂先生为公司持股 5%以上股东，现任公司董事长兼总裁， 蔡南桂先生之配偶唐霖女士现任公司董事。根据《深圳证券交易所股票上市规则》 等法律、法规及规范性文件的规定，蔡南桂先生为公司 ...

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-041 赛隆药业集团股份有限公司 第四届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 赛隆药业集团股份有限公司（以下简称"公司"）第四届监事会第九次会议 通知于 2025 年 7 月 11 日以专人送达、电子邮件、电话相结合的方式送达各位监 事。会议于 2025 年 7 月 14 日在湖南省长沙市长沙县星沙产业基地红枫路 1 号湖 南赛隆药业（长沙）有限公司会议室以现场和通讯相结合的方式召开，本次会议 应出席监事 3 人，实际出席监事 3 人。会议由监事会主席周蓓女士召集和主持。 本次会议的召集、召开程序符合《公司法》等有关法律、法规、规范性文件及《公 司章程》的规定。 三、备查文件 1.第四届监事会第九次会议决议。 特此公告。 赛隆药业集团股份有限公司 监事会 2025 年 7 月 15 日 二、监事会会议审议情况 1.审议并通过了《关于公司向关联方借款暨关联交易的议案》 具体内容详见同日刊登于巨潮资讯网（www.cninfo.com.cn ...